Bristol-myers Squibb Compnay

The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Company

Bristol Meyers Squibb Company

Dupont Pharmaceuticals, Inc.

William John Pitts

Junqing Guo

Steven H Spergel

John T Hynes

Scott Hunter Watterson

Sreekantha Ratna Kumar

Ramesh Kumar Sistla

Satheesh Kesavan Nair

Joseph Barbosa

Venkatram Reddy Paidi

Douglas G Batt

Amy C Hart

Carolyn Diane Dzierba

James Kempson

John E Macor

Michael J Orwat

Jagabandhu Das

Alaric J Dyckman

Sing-Yuen Sit

Guanglin Luo

Rajeev S Bhide

Jie Chen

Hong Wu

Abhisek Banerjee

T G Murali Dhar

John V Duncia

Jingwu Duan

Joseph B Santella

Natesan Murugesan

Daniel S Gardner

Bin Jiang

Yuping Qiu

Zhonghui Lu

Jianliang Shi

Ronald L Magolda

Carl Henry Behrens

Michael E Mertzman

Irina Cipora Jacobson

Katerina Leftheris

Makonen Belema

Prabhakar Kondaji Jadhav

Edwin J Iwanowicz

Henry H Gu

Murugaiah Andappan Murugaiah Subbaiah

Claude Quesnelle

Chunjian Liu

Bingwei Vera Yang

Donald J Pinto

Patrice Gill

Fred Christopher Zusi

Charles Malcolm Langevine

Lihua Chen

Joseph J Petraitis

Jason M Guernon

Gregory D Brown

Joseph Anthony Tino

John Wityak

Stephen T Wrobleski

Yong-Jin Wu

Dharmpal S Dodd

Wayne D Vaccaro

Gregory S Bisacchi

Hai-Yun Xiao

Matthew Ernst Voss

Jacques Y Roberge

John L Gilmore

Christopher P Mussari

Harold A Mastalerz

Khehyong Ngu

Brian Lee Venables

Ryan M Moslin

Shuqun Lin

Trevor C Sherwood

Timothy F Herpin

Zhizhen Barbara Zheng

Hua Gong

F Christopher Zusi

Marianne Carlsen

Arnold J Repta

Munir A Hussain

Xuejie Yang

Arun Kumar Gupta

Samayamunthula Venkata Satya Arun Kumar Gupta

Marco Dodier

Carolyn A Weigelt

Joanne Marie Smallheer

Ning Li

Charles M Langevine

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Indazole carboxamides as kinase inhibitors

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CRor N; B is CRor N; D is CRor N; Lis &#x2014;(CRR)&#x2014;; Lis &#x2014;(CRR)&#x2014;; and X, Z, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Heterocyclic compounds useful as modulators of TNF alpha

Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Heteroaryl substituted pyridyl compounds useful as kinase modulators

Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein. 

Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors

Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C&#x2014;R, are useful as kinase modulators, including IRAK-4 modulation.

Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition. 

Growing community of inventors

Newtown, PA, United States of America

William John Pitts